Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Microbicides news

Show

From To
Model Explains Why HIV Prevention Dosing Differs by Sex

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex. This finding helps explain why two large clinical trials testing HIV pre-exposure prophylaxis, or PrEP, in women failed to show efficacy

Published
2 hours ago
From
National Institute of Allergy and Infectious Diseases (NIAID) press release
Tenofovir gel use associated with lower HSV-2 risk in women

The risk of acquiring herpes simplex virus type 2 (HSV-2) was reduced by 46% (aIRR:0.54, 95%CI:0.30-0.97, p=0.038) among women who regularly used the vaginal gel containing tenofovir, according

Published
30 October 2014
By
Lesley Odendal
HIV R4P: Conference co-chair and “vaginal ecologist” Sharon Hillier talks about “the beautiful ecosystem,” and how to make it more resistant to HIV

“People around the world have mysterious notions about the vagina,” Sharon Hillier told a group of journalists and advocates today. Hillier, one of five co-chairs of HIV R4P, the first global conference devoted to biomedical HIV prevention research, is here to explain her work, which she sums up as making vaginas much more resistant to […](Read more...)

Published
28 October 2014
From
Science Speaks
Are antimicrobial condoms the new frontier against STIs? Not quite…

Australian biotech company Starpharma has announced the imminent launch of a condom coated with an antimicrobial chemical known as VivaGel. While it might be marketed as a great leap forward for preventing sexually transmitted infections (STIs), it’s unlikely to offer any more protection than your average condom.

Published
14 October 2014
From
The Conversation
Advocates Applaud Launch of MTN-017, World’s First Phase II Rectal Microbicide Study

IRMA applauds the launch of the world’s first-ever Phase II rectal microbicide trial. The Microbicide Trial Network’s study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally. Volunteers consisting of gay men, other men who have sex with men, and transgender women will participate in the study at sites in the United States and in Thailand, South Africa, and Peru.

Published
02 October 2014
From
IRMA
Give Some LOVE to IRMA for Give OUT Day

Give OUT Day shines a spotlight on organizations that empower LGBTQ communities across the country, and the AIDS Foundation of Chicago (AFC) is among these charities.We’re using this campaign to highlight the next generation of HIV prevention: rectal microbicides. Though they’re still in development, these agents can be added to things like lubricants that will prevent the transmission of HIV, revolutionizing the way we protect ourselves and others.

Published
25 September 2014
From
IRMA
Stigma, ambivalence and other priorities – explaining poor adherence to PrEP and vaginal microbicides

HIV stigma, the danger of being mistakenly labelled as having HIV, ambivalence about the research process, confusion about the use of antiretrovirals to prevent infection, as well

Published
19 September 2014
By
Roger Pebody
HIV-fighting intravaginal ring research nets $20M from NIH

The U.S. National Institutes of Health devoted $20 million to a group of institutions including Miriam Hospital in Rhode Island to develop an HIV drug-delivering intravaginal ring. The design of a successful ring is a priority in HIV research, and the sustained release of drugs the ring offers could eventually play a crucial role in HIV prevention in the developing world.

Published
15 September 2014
From
Fierce Drug Delivery
Learning about additional HIV prevention methods doesn’t undermine gay men’s intentions to use condoms

Health promotion interventions can combine information about condoms and alternative biomedical prevention methods without undermining attitudes and intentions to use condoms, according to an experimental study published in

Published
15 September 2014
By
Roger Pebody
Semi-soft vaginal drug-delivery suppository could limit spread of HIV, AIDS

A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, thanks to researchers in Penn State's College of Agricultural Sciences. A semi-soft vaginal suppository made from the seaweed-derived food ingredient carrageenan and loaded with the antiviral drug Tenofovir provides a woman-initiated, drug-delivery vehicle that can protect against the spread of sexually transmitted infections during unprotected heterosexual intercourse, the researchers said.

Published
02 September 2014
From
Medical News Today
← First12345...19Next →

Filter by country